Indications for Metformin
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus 1.
Primary FDA-Approved Indication
The FDA-approved indication is straightforward: metformin is used for glycemic control in type 2 diabetes 1. This applies to:
- Adults with type 2 diabetes
- Pediatric patients ≥10 years of age with type 2 diabetes
The medication must be used alongside diet and exercise modifications, not as monotherapy without lifestyle interventions 1.
Clinical Guideline-Supported Use in Type 2 Diabetes
For adults with type 2 diabetes who require glucose-lowering therapy without additional comorbidities (no established cardiovascular disease, heart failure, or chronic kidney disease), metformin remains a commonly used first-line medication 2. The 2025 ADA Standards of Care emphasize that metformin is:
- Effective and safe with proven reduction in microvascular complications, cardiovascular events, and death 2
- Inexpensive and widely available 2
- Weight neutral (does not cause weight gain) 2
- Does not cause hypoglycemia when used alone 2
- Superior to sulfonylureas in reducing cardiovascular mortality 2
- More effective than DPP-4 inhibitors in lowering A1C and weight 2
Important Context on First-Line Status
While metformin has historically been the default first-line agent 2, 3, current guidelines prioritize treatment selection based on comorbidities. If a patient has established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, agents with proven cardiorenal benefits (GLP-1 RAs or SGLT2 inhibitors) should be prioritized regardless of metformin use 3. Metformin remains appropriate for patients without these compelling indications for other agents.
Dosing Parameters
Adults
- Starting dose: 500 mg twice daily OR 850 mg once daily with meals 1
- Titration: Increase by 500 mg weekly or 850 mg every 2 weeks based on glycemic control and tolerability 1
- Maximum dose: 2,550 mg/day in divided doses (doses >2,000 mg better tolerated three times daily) 1
Pediatric Patients (≥10 years)
- Starting dose: 500 mg twice daily with meals 1
- Titration: Increase by 500 mg weekly 1
- Maximum dose: 2,000 mg/day in divided doses 1
Renal Function Requirements and Contraindications
Metformin is contraindicated when eGFR is <30 mL/min/1.73 m² 1. Specific renal considerations include:
- eGFR ≥45 mL/min/1.73 m²: Safe to initiate and continue 1
- eGFR 30-45 mL/min/1.73 m²: Initiation NOT recommended; if already on metformin, assess benefit-risk of continuing 1
- eGFR <30 mL/min/1.73 m²: Discontinue metformin 1
Iodinated Contrast Procedures
Discontinue metformin before iodinated contrast imaging in patients with eGFR 30-60 mL/min/1.73 m², history of liver disease, alcoholism, heart failure, or those receiving intra-arterial contrast 1. Re-evaluate eGFR 48 hours post-procedure before restarting 1.
Additional Contraindications
Metformin is contraindicated in 1:
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Hypersensitivity to metformin
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Common Pitfalls and Side Effects
Gastrointestinal Intolerance
The most common side effects are bloating, abdominal discomfort, and diarrhea 2, 3. Mitigate these by gradual dose titration and/or using extended-release formulations 2.
Vitamin B12 Deficiency
Metformin use is associated with increased risk of vitamin B12 deficiency and worsening neuropathy symptoms 2. Periodic testing of vitamin B12 levels is recommended 2.
Lactic Acidosis Risk
While lactic acidosis is the most feared complication, it is extremely rare and primarily occurs when eGFR is <30 mL/min/1.73 m² 2. The risk is heightened with acute kidney injury or overdose 2.
Off-Label and Investigational Uses
While the FDA-approved indication is limited to type 2 diabetes 1, research suggests potential benefits in multiple other conditions 4, 5, 6:
Established Off-Label Uses (Variable Evidence)
- Polycystic ovarian syndrome (PCOS) 4
- Gestational diabetes/diabetes in pregnancy 4
- Prevention of type 2 diabetes in prediabetes 4
- Adjunct therapy in type 1 diabetes 4
Investigational Uses Under Study
- Cancer prevention and treatment 4, 5
- Alzheimer's disease and cognitive impairment 4, 5
- Metabolic dysfunction-associated steatotic liver disease (MASLD) 4
- Renal protection 4
- Prevention of antipsychotic-induced weight gain 7
Note: Many off-label uses lack contemporary evidence-based medicine support and vary by regulatory territory 4. For NAFLD specifically, recent evidence suggests metformin may worsen inflammation and should NOT be used for this purpose 5.